0
ARTICLE |

CURRENT STATUS OF ARYL SULFONYLUREAS IN TREATMENT OF DIABETES MELLITUS

Roger H. Unger, M.D.; Joseph W. Davidson Jr., M.D.
JAMA. 1956;162(5):447-453. doi:10.1001/jama.1956.02970220011004.
Text Size: A A A
Published online

• Tolbutamide, an aryl sulfonylurea closely related to carbutamide, was used in the treatment of 18 diabetic patients. Three were patients with diabetes of the severe labile type in whom insulin shock and ketosis were never far apart; six had moderately severe stable adult diabetes in which insulin had been required for adequate control; six had mild stable adult diabetes that could be adequately controlled by carbohydrate restriction without insulin; three had very mild adult diabetes. After a sevenday control period to establish base lines, the daily administration of tolbutamide was begun. The usual starting dose was 3 gm. by mouth as a 2% solution of tolbutamide in 0.5 % sodium bicarbinate solution. The patients with labile diabetes receiving insulin did not benefit from tolbutamide in large doses, and profound hypoglycemic shock was encountered in one. The best results were seen among the 12 patients who had stable diabetes requiring treatment of some sort; in 7 of these, the daily oral administration of tolbutamide in doses of 3 to 6 gm. per day diminished fasting hyperglycemia and suppressed glycosuria, but only one of the 7 had been in the group previously requiring insulin for adequate control of diabetes.

Topics

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

Figures

Tables

References

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();